Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

KEYNOTE-177

- PMLiVE

Young diabetes patients in England and Wales receive fewer vital checks

Less than a third with type 1 diabetes receive eight of nine recommended care processes

- PMLiVE

NICE recommends Lundbeck’s alcohol dependency drug

NHS patients to have access to Selincro to help control drinking

- PMLiVE

PD1 drugs could end ‘decades of silence’ in bladder cancer therapy

Merck's Keytruda and Roche antibody showing promise

National Institute for Health and Care Excellence NICE logo

Remicade, Humira and Simponi face NICE knock-back

Draft guidance does not recommend the drugs for ulcerative colitis

- PMLiVE

NICE backs Celgene’s Revlimid in rare blood cancer

Patient access scheme sways the HTA body

- PMLiVE

NICE fast-tracks GSK’s skin cancer drug Tafinlar

But only on condition the company cuts its price

Eli Lilly HQ

Lilly closes in on another Cyramza indication

Could be used for colorectal cancer in addition to stomach cancer

National Institute for Health and Care Excellence NICE logo

NICE wants greater access to clinical data

Will turn to European regulators if companies fail to provide information

- PMLiVE

NICE knocks back Celgene’s Abraxane in pancreatic cancer

Says cancer drug's cost not justified by its limited benefit

Bristol-Myers Squibb (BMS) building

BMS takes PD-1 rivalry with Merck to the law courts

Claims Keytruda infringes antibody patents it holds with Ono Pharmaceutical

- PMLiVE

Merck brings first PD-1 inhibitor to US market

FDA approves Keytruda for advanced melanoma

- PMLiVE

England’s Cancer Drugs Fund: Naughty or NICE?

The decision to extend the CDF raises questions on the future of cancer drug access on the NHS

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links